Last reviewed · How we verify
A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) or apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with apatinib (375 mg qd).
Details
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 54 |
| Start date | 2020-05 |
| Completion | 2021-06 |
Conditions
- Ovarian Cancer
Interventions
- Apatinib and Etoposide capsule
- Apatinib
Primary outcomes
- Objective response rate (ORR) by investigator — up to 2 years
ORR was defined as the proportion of subjects who have a complete or partial response relative to baseline .